Medivir AB (publ) (STO:MVIR)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.604
-0.106 (-6.20%)
At close: Feb 27, 2026
-16.02%
Market Cap 864.03M
Revenue (ttm) 8.50M
Net Income (ttm) -94.40M
Shares Out 538.67M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,582,025
Average Volume 15,287,849
Open 1.670
Previous Close 1.710
Day's Range 1.550 - 1.724
52-Week Range 0.340 - 2.195
Beta -0.05
RSI 66.90
Earnings Date Feb 18, 2026

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phase II studies for treating mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1987
Employees 10
Stock Exchange Nasdaq Stockholm
Ticker Symbol MVIR
Full Company Profile

Financial Performance

In 2025, Medivir AB's revenue was 8.50 million, an increase of 143.97% compared to the previous year's 3.48 million. Losses were -94.40 million, -23.45% less than in 2024.

Financial Statements

News

There is no news available yet.